Skip to main content

Table 3 Median densities of various immune marker–expressing cells in NSCLCs from patients who received neoadjuvant chemotherapy (NCT) or did not receive NCT (non-NCT), by tumor histology (N = 112)

From: Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Markers

ADC (n = 64)

P a

SCC (n = 51)

P a

non-NCT

NCT

non-NCT

NCT

Median Cell Density (cells/mm2)

Median Cell Density (cells/mm2)

Panel 1

 MCs (AE1/AE3+)

3135.42

3043.84

0.841

4125.37

3641.55

0.554

 MCs PD-L1+

13.45

362.92

0.007

317.91

944.99

0.593

 CD3+

916.14

1406.72

0.133

811.47

1825.85

0.070

 CD3 + CD4+

671.49

997.47

0.170

650.63

1360.68

0.072

 CD3 + CD8+

157.39

212.85

0.647

155.34

358.93

0.842

 CD68+

298.80

591.42

0.430

321.12

705.60

0.040

 CD68 + PD-L1+

196.71

222.96

0.600

172.72

357.54

0.090

Panel 2

 MCs (AE1/AE3+)

3134.08

2596.71

0.299

4528.99

3703.28

0.352

 CD45RO+

623.31

595.51

0.484

723.46

1356.35

< 0.001

 CD45RO + CD57 + granzyme B−

240.95

332.13

0.008

118.68

395.21

0.013

 CD45RO + PD1+

170.47

243.04

0.016

112.40

380.26

0.007

 CD45RO + FOXP3+

7.17

7.17

0.448

4.18

9.56

0.073

 CD57 + granzyme B+ CD45RO−

4.26

40.65

< 0.001

9.86

9.86

0.925

 PD-1+

426.90

718.68

0.014

273.84

1314.49

< 0.001

  1. ADC adenocarcinoma, SCC squamous cell carcinoma, MC malignant cells
  2. aMann Whitney U test